Hospital Acquired Disease Testing Market 2023-2028 Research Report | Global Leading Players Analysis Like Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd and More

According to the latest report by IMARC Group, titled "Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028", offers a comprehensive analysis of the industry, which comprises insights on the global market statistics. The report also includes competitor and regional analysis, and contemporary advancements in the global market.

Year considered to estimate the market size:

• Base year of the analysis: 2022
• Historical period: 2017-2022
• Forecast period: 2023-2028

The global hospital acquired disease testing market size reached US$ 10.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 27.7 Billion by 2028, exhibiting a growth rate (CAGR) of 17.57% during 2023-2028.

Download a free sample report to get a detailed overview of the market: https://www.imarcgroup.com/hospital-acquired-disease-testing-market/requestsample

Hospital Acquired Disease Testing Market Insight:

Hospital-acquired infections (HAIs) or nosocomial infections represent the diseases that are contracted in hospitals and medical clinics. Nosocomial refers to infections or diseases originating in a hospital. A person can get such illnesses even in the vicinity of a rehabilitation center, nursing home, hospital, or any other clinical surroundings. Most people acquire HAIs when they are in emergency rooms (ERs) and intensive care units (ICUs). Typically, the gestation period of these diseases varies between 48 hours to 4 days after the individual gets admitted.

The primary reason behind the cause of hospital-acquired diseases is the absence of proper hygiene in the hospital settings. Other reasons comprise complacency by the hospital staff, below-par maintenance, and a rise in multi-drug resistant organisms (MDROs). Commonly occurring nosocomial infections include primary bloodstream infections, pneumonia, urinary tract infections (UTIs), surgical site infections (SSIs), etc. In most cases, it has also been found that these diseases are sometimes traced to the own microbiome of the patient. It happens when the protective layer of the skin comes in communication with possible threats and causes infection to occur.

Hospital Acquired Disease Testing Market Growth Drivers:

The escalating number of healthcare facilities across the globe, owing to the rising population and modernization of the healthcare infrastructure, is among the primary factors driving the hospital acquired disease testing market. Besides this, the introduction of innovative and advanced techniques, such as polymerase chain reaction (PCR), real-time location systems (RTLSs), microarrays, and solid phase hybridization for preventing, diagnosing, and monitoring infections, is further augmenting the market growth. Moreover, the increasing awareness among the masses toward the benefits of early detection of these illnesses is anticipated to propel the hospital acquired disease testing market over the forecasted period. 

Hospital Acquired Disease Testing Market 2023-2028 Competitive Analysis and Segmentation:

Competitive Landscape With Key Players:

The competitive landscape of the hospital acquired disease testing market has been studied in the report with the detailed profiles of the key players operating in the market.

Key Companies in the Global Hospital Acquired Disease Testing Market:

• Abbott Laboratories
• Alere, Inc.
• Becton, Dickinson and Company
• bioMérieux SA
• Hoffmann-La Roche Ltd.
• Hologic, Inc.
• QIAGEN
• Siemens Healthcare
• Diatherix Laboratories, Inc.
• Meridian Bioscience, Inc.
• Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
• Cepheid, Inc.

Hospital Acquired Disease Testing Market Segmentation:

The report has segmented the hospital acquired disease testing market on the basis of indication and region.

Based on Indication:

• UTI (Urinary Tract Infection)
• SSI (Surgical Site Infection)
• Pneumonia
• Bloodstream Infections
• MRSA (Methicillin-Resistant Staphylococcus Aureus)
• Others

Geographical Analysis:

• North America: (United States, Canada)
• Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America: (Brazil, Mexico, Others)
• Middle East and Africa

Get in Touch with our Expert Team for Inquire or Further Information: https://www.imarcgroup.com/request?type=report&id=1128&flag=C

Key Highlights of the Report:               

• Market Performance (2017-2022)
• Market Outlook (2023-2028)
• Industry Trends
• Market Drivers and Success Factors
• The Impact of COVID-19 on the Global Market
• Value Chain Analysis
• Structure of the Global Market
• Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

You Might Also Read:

Surface Disinfectant Market Share and Growth Drivers 2022-2027: https://www.imarcgroup.com/surface-disinfectant-market

eClinical Solutions Market Report: https://www.digitaljournal.com/pr/the-future-looks-bright-for-eclinical-solutions

Contact US:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

About Us                                    

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.